Skip to main content
SpringerLink
Log in

Comparison of in vitro and in vivo biotransformation in patients with liver disease of differing severity

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The activity of 7-ethoxycoumarin O-deethylase (ECOD) has been measured in liver biopsy samples from 23 patients (smokers and non-smokers) with different degrees of structural liver damage. The results, which reflect in vitro cytochrome P450-dependent biotransformation, were correlated with various measures of the P450-dependent in vivo elimination of caffeine and metamizol.

The relatively non-specific, low affinity component of ECOD activity was significantly correlated with the kinetics of metamizol (mean residence time, apparent clearance, half-life, area under the concentration-time curve, and metabolite excretion in the urine). Thus, metamizol elimination, which is mainly due to P450 IIB, and the low affinity component of ECOD both reflect, at least in part, the activity of the same form of P450. In contrast, caffeine biotransformation, which is via P450 IA, was not correlated with ECOD activity.

There was no relation between the kinetics of metamizol and caffeine, perhaps because of the inducing effect that smoking has on caffeine elimination.

In patients with liver disease, smoking appears to alter the elimination of caffeine more than the degree of liver disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Brodie MJ, Boobis AR, Bulpitt CJ, Davies DS (1981) Influence of liver disease and environment factors on hepatic monooxygenase activity in vitro. Eur J Clin Pharmacol 20: 39–46

    Google Scholar 

  2. Farrell GC, Cooksley WGE, Powell LW (1979) Drug metabolism in liver disease: activity of hepatic microsomal metabolizing enzymes. Clin Pharmacol Ther 26: 483–492

    Google Scholar 

  3. Sotaniemi EA, Niemelä O, Risteli L, Stenbäck F, Pelkonen RO, Lahtela JT, Risteli J (1986) Fibrotic process and drug metabolism in alcoholic liver disease. Clin Pharmacol Ther 40: 46–55

    Google Scholar 

  4. Zilly W, Richter E (1983) Coffein bei chronischen Lebererkrankungen. Dtsch Med Wochenschr 108: 477–478

    Google Scholar 

  5. May B, Helmstaedt D, Büstgens L, McLean A (1974) The relationship between cytochrome P450 in liver biopsies and drug metabolism in patients with liver disease and in morphine addiction. Dig Sci Mol Med 46: 11 P

  6. Wensing G, Hoensch HP, Ohnhaus EE (1989) Correlation between microsomal enzyme activity and antipyrine elimination in alcoholics and nonalcoholics with various liver diseases. Clin Pharmacol Ther 45: 166

    Google Scholar 

  7. Woodhouse KW, Williams FM, Mutch E, Wright P, James OFW, Rawlins MD (1984) The effect of alcoholic cirrhosis on the two kinetic components (high and low affinity) of the microsomal O-deethylation of 7-ethoxycoumarin in human liver. Eur J Clin Pharmacol 26: 61–64

    Google Scholar 

  8. Greenlee WF, Poland A (1978) An improved assay of 7-ethoxycoumarin O-deethylase activity: induction of hepatic enzyme activity in C57BL/6J and DBA/2J mice by phenobarbital, 3-methylcholanthrene and 2,3,7,8-tetrachlorodibenzo-p-dioxin. J Pharmacol Exp Ther 205: 596–605

    Google Scholar 

  9. Guengerich FP, Dannan GA, Wright ST, Martin MV, Kaminsky LS (1982) Purification and characterization of liver microsomal cytochromes P-450: electrophoretic, spectral, catalytic, and immunochemical properties and inducibility of eight isozymes isolated from rats treated with phenobarbital or naphthoflavone. Biochemistry (USA) 21: 6019–6030

    Google Scholar 

  10. Campbell ME, Grant DM, Inaba T, Kalow W (1987) Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes. Drug Metab Dispos 15: 237–249

    Google Scholar 

  11. Ratanasavanh D, Berthou F, Dreano Y, Mondine P, Guillouzo, Riche C (1990) Methylcholanthrene but not phenobarbital enhances caffeine and theophylline metabolism in cultured adult human hepatocytes. Biochem Pharmacol 39: 85–94

    Google Scholar 

  12. Nebert DW, Adesnik M, Coon MJ, Estabrook RW, Gonzalez FJ, Guengerich FP, Gunsalus IC, Johnson EF, Kemper B, Levin W, Phillips IR, Sato R, Watermann MR (1987) The P450 gene superfamily: recommended nomenclature. DNA 6: 1–11

    Google Scholar 

  13. Butler MA, Iwasaki M, Guengerich FP, Kadlubar F (1989) Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci USA 86: 7696–7700

    Google Scholar 

  14. Roots I, Saalfranck K, Hildebrandt AG (1975) Comparison of methods to study enzyme induction in man. In: Cooper DY, Rosenthal O, Snyder R, Witmer C (eds) Cytochromes P-450 and b5. Plenum Press, New York, pp 485–502

    Google Scholar 

  15. Conney AH (1967) Pharmacological implications of microsomal enzyme induction. Pharmacol Rev 19: 317–366

    Google Scholar 

  16. Volz M, Kellner H-M (1980) Kinetics and metabolism of pyrazolones (propyphenazone, aminopyrine and dipyrone). Br J Clin Pharmacol 10: 299S-308S

    Google Scholar 

  17. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye-binding. Anal Biochem 72: 248–254

    Google Scholar 

  18. Werner M (1982) Qualitative and quantitative Bestimmung von Aminophenazonmetaboliten in verschiedenen Körperflüssigkeiten. Dissertation A, Martin-Luther-Universität, Halle, Wittenberg, FRG

    Google Scholar 

  19. Emerson E, Beacham HH, Beegle LC (1943) The condensation of aminoantipyrine. II. A new color test for phenolic compounds. J Org Chem 8: 417–428

    Google Scholar 

  20. Woodhouse KW, Williams FM, Mutch E, Wright P, James OFW, Rawlins MD (1983) The effect of alcoholic cirrhosis on the activities of microsomal aldrin epoxidase, 7-ethoxycoumarin 0-deethylase and epoxide hydrolase, and on the concentrations of reduced glutathione in human liver. Br J Clin Pharmacol 15: 667–672

    Google Scholar 

  21. Hoensch H, Hartmann F, Schomerus H, Bieck P, Dölle W (1979) Monooxygenase enzyme activity in alcoholics with varying degrees of liver damage. Gut 20: 666–672

    Google Scholar 

  22. Hoensch HP, Hutzel H, Kirch W, Ohnhaus EE (1985) Isolation of human hepatic microsomes and their inhibition by cimetidine and ranitidine. Eur J Clin Pharmacol 29: 199–206

    Google Scholar 

  23. Truckenbrodt J, Kraul H, Machnik G, Volland R, Hoffmann A (1989) Studies on the in-vitro biotransformation in patients with liver diseases. Gastroenterol J 49: 126–128

    Google Scholar 

  24. Hoensch HP, Schreier I, Ohnhaus EE (1986) Inducing efficacy of ethanol on hepatic drug metabolizing enzymes in patients. Eur J Clin Invest 16: 284–291

    Google Scholar 

  25. Remmer H (1976) Drug metabolism in the human liver measured with in vitro and in vivo methods. Drug Res 26: 1262

    Google Scholar 

  26. Yanev S, Grahovska T, Stoytchev T (1986) Analgin — effects on liver drug metabolism. Symposium Drug Metabolizing Enzyme Systems, Sofia, May 20–22

  27. Imaoka S, Inoue K, Funae Y (1988) Aminopyrine metabolism by multiple forms of cytochrome P-450 from rat liver microsomes: simultaneous quantitation of four aminopyrine metabolites by high-performance liquid chromatography. Arch Biochem Biophys 265: 159–170

    Google Scholar 

  28. Pederson TC, Aust SD (1970) Aminopyrine demethylase — kinetic evidence for multiple microsomal activities. Biochem Pharmacol 19: 2221–2230

    Google Scholar 

  29. Scott NR, Stambuk D, Chakraborty J, Marks V, Morgan MY (1989) The pharmacokinetics of caffeine and its dimethylxanthine metabolites in patients with chronic liver disease. Br J Clin Pharmacol 27: 205–213

    Google Scholar 

  30. Desmond PV, Patwardhan RV, Johnson RF, Schenker S (1980) Impaired elimination of caffeine in cirrhosis. Dig Dis Sci 25: 193–197

    Google Scholar 

  31. Joeres R, Klinker H, Heusler H, Epping J, Zilly W, Richter E (1988) Influence of smoking on caffeine elimination in healthy volunteers and in patients with alcoholic liver cirrhosis. Hepatology 8: 575–579

    Google Scholar 

  32. Murphy TL, McIvor C, Yap A, Cooksley WG, Halliday JW, Powell LW (1988) The effect of smoking on caffeine elimination: implicated for the use as a semiquantitative test of liver function. Clin Exp Pharmacol Physiol 15: 9–13

    Google Scholar 

  33. Pelkonen O, Sotaniemi E, Tokola O, Ahokas JT (1980) Correlations between cytochrome P-450 and oxidative metabolism of benzo(a)pyrene and 7-ethoxycoumarin in human liver in vitro and antipyrine elimination in vivo. Drug Metab Dispos 8: 218–222

    Google Scholar 

  34. Sotaniemi EA, Pelkonen RO, Ahokas JT, Pirttiaho HI, Ahkqvist J (1978) Relationship between in vivo and in vitro drug metabolism. Eur J Drug Metab Pharmacokinet 1: 39–45

    Google Scholar 

  35. Vuitton D, Miguet JP, Camelot G, Delafin C, Joanne C, Bechtel P, Gillet M, Carayon P (1981) Relationship between metabolic clearance rate of antipyrine and hepatic microsomal drug-oxidizing enzyme activities in humans without liver disease. Gastroenterol 80: 112–118

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Clinical Pharmacology, Friedrich Schiller University, Jena, FRG

    H. Kraul, A. Huster, R. Töpfer & A. Hoffmann

  2. Department of Internal Medicine, Friedrich Schiller University, Jena, FRG

    J. Truckenbrodt

Authors
  1. H. Kraul
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Truckenbrodt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Huster
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Töpfer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Hoffmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kraul, H., Truckenbrodt, J., Huster, A. et al. Comparison of in vitro and in vivo biotransformation in patients with liver disease of differing severity. Eur J Clin Pharmacol 41, 475–480 (1991). https://doi.org/10.1007/BF00626373

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00626373

Key words

Search

Navigation